공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

NTRK 융합 유전자 양성암 - KOL에 의해 검증된 역학 연구 : 기회 평가, 시장 역학, 파이프라인 분석(2020년 하반기)

KOL Validated Epidemiological Studies of NTRK Gene Fusion Positive Cancers, Opportunity Assessments, Market Dynamics, and Pipeline Analytics H2 2020

리서치사 GervanoRA Data Services LLP
발행일 2020년 12월 상품 코드 979838
페이지 정보 영문 291 Pages
가격
US $ 6,000 ₩ 6,960,000 PDF (Single User License)
US $ 9,000 ₩ 10,440,000 PDF (Site License)
US $ 11,000 ₩ 12,761,000 PDF (Global License)


NTRK 융합 유전자 양성암 - KOL에 의해 검증된 역학 연구 : 기회 평가, 시장 역학, 파이프라인 분석(2020년 하반기) KOL Validated Epidemiological Studies of NTRK Gene Fusion Positive Cancers, Opportunity Assessments, Market Dynamics, and Pipeline Analytics H2 2020
발행일 : 2020년 12월 페이지 정보 : 영문 291 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 NTRK 융합 유전자 양성암(NTRK Gene Fusion Positive Cancer) 치료제 시장에 대해 조사했으며, 시장 기회, 성장 촉진요인 및 억제요인, 개발 단계·지역·투여 경로·분자 유형·적응증·기업 유형별 파이프라인 분석, 임상시험, 경쟁 구도 및 신규 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 보고서 개요
  • 조사 방법
  • 당사에 대해

제2장 개요

  • 보고서 개요
  • TRK 저해제 경쟁 공간에서의 주요 이벤트
  • 주요 조사 결과 보고
    • 성장요인
    • 억제요인
    • 시장 기회
  • TRK 저해제 경쟁 구도의 시장 역학
    • 새로운 치료법의 충족되지 않은 욕구와 시장 수요
    • 충족되지 않은 욕구와 시장 수요 : 투여 경로별
    • 충족되지 않은 욕구와 시장 수요 : 지역별

제3장 파이프라인 분석 전망

  • 파이프라인 분석 비교 현황
    • 개발 단계별
    • 지역별
    • 투여 경로별
    • 분자 유형별
    • 적응증별
    • 기업 유형별

제4장 TRK 저해제 요법 개요와 역학 연구

  • 서론
  • TRK 저해제 요법 - 개발 평가
  • TRK 저해제 요법의 범위
  • NTRK 융합 암환자 발견
  • 암에서의 NTRK 융합 유전자 발견
  • 승인을 획득한 TRK 저해제 제품
  • 융합 NTRK 유전자 역학 연구
    • 세계 및 과거 동향
    • NTRK 융합 유전자 유병률 연구
    • NTRK 융합 유전자 발생률 연구
    • TRK 저해제를 투여하는 추정 환자수

제5장 TRK 저해제 관련 거래(M&A) 분석

  • 거래(합병/인수/협업)

제6장 TRK 저해제 특허 분석 파이프라인약

제7장 TRK 저해제 파이프라인 약물 분석

  • 개발 단계별 파이프라인 의약품 분석
    • 사전 등록 단계
    • PHASE III
    • PHASE II
    • PHASE I
    • 전임상
    • 초기 R&D
    • 비활성 및 중단
  • 지역별
  • 투여 경로별
    • 경구투여 경로별
    • 국소 및 주사 ROA별
  • 분자 유형별
  • 타깃 수용체별
  • 적응증별
  • 기업 유형별

제8장 파이프라인 개요와 개발 마일스톤

  • 사전 등록
  • PHASE III
  • PHASE II
  • PHASE I

제9장 임상시험 개요

  • 임상시험 결과별 분석
    • 주요 PHASE III 임상시험 결과
    • 주요 PHASE II 임상시험 결과
    • 주요 PHASE I 임상시험 결과
  • 진행중인 임상시험 개요
  • 최근 완료된 임상시험 개요
  • 계획된 임상시험 개요

제10장 파이프라인의 추정 승인 타임라인

  • 조사 방법
  • 미국 및 미국 이외의 추정 승인 스케줄

제11장 경쟁 벤치마킹을 통한 기회 평가

제12장 현재 및 향후 경쟁 구도

  • 신규 기업
    • 신규 기업 개요
LSH 21.01.13

GervanoRA's pipeline analysis and opportunity assessment report "KOL Validated Epidemiological Studies of NTRK Gene Fusion Positive Cancers, Opportunity Assessments, Market Dynamics, and Pipeline Analytics H2 2020" provides detailed analytics on the Epidemiology of NTRK Gene Fusion Cancers in different regions worldwide through a keen full assessment on historical and global trends of prevalence and incidence of NTRK gene fusion-positive cancers. Based on a literature survey and further validation through the KOL process, the report emphasizes finding out the affected population with NTRK gene fusion-positive cancers by geography (US, Europe, and Worldwide) and by majorly affected cancer types. The report even provides insights on TRK Inhibitors' foreseen market opportunities considering the TRK Inhibitor therapies are the only option to treat NTRK gene fusion-positive cancers. Report further analyzed and assessed the total forecasted market into two portions considering broader scope the TRK Inhibitors to treat indications like Neurodegenerative Diseases, Gastrointestinal Diseases and addiction conditions other than NTRK gene fusion-positive cancers. The report outlines how many people can undergo TRK Inhibitor therapies by 2029, and potential market value of NTRK gene fusion-positive cancers, and the market value of TRK Inhibitors meant to treat other indications other than NTRK gene fusion-positive cancers.

TRK Inhibitors pipeline molecules have been analysed for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitor drugs development pipeline.

The report has been divided into segments like TRK InhibitorsTherapies Overview and Epidemiological Studies, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the TRK Inhibitors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target, Pipeline Analytics by Indication and Pipeline Analytics by Company Type.

The report has covered more than 50 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)

Epidemiological Studies of NTRK Gene Fusion Positive Cancers

  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage Pipeline Drug Candidates and Filed Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Plotting of the Anticipated Market Share for the New Entrants (Filed, Phase 3 and Phase 2 Drugs)
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE TRK INHIBITORS COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES
  • 2.4. MARKET DYNAMICS OF TRK INHIBITORS COMPETITIVE LANDSCAPE
    • 2.4.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES
    • 2.4.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION
    • 2.4.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

  • 3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS
    • 3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT
    • 3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY
    • 3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION
    • 3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE
    • 3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY INDICATION
    • 3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

CHAPTER 04: TRK INHIBITORS THERAPIES OVERVIEW AND EPIDEMIOLOGICAL STUDIES

  • 4.1. INTRODUCTION
  • 4.2. TRK INHIBITORS THERAPIES - DEVELOPMENT ASSESSMENTS
  • 4.3. SCOPE OF TRK INHIBITORS THERAPIES
  • 4.4. DETECTION OF PATIENTS WITH NTRK FUSION CANCERS
  • 4.5. DISCOVERY OF NTRK GENE FUSIONS IN CANCERS
  • 4.6. APPROVED TRK INHIBITOR PRODUCTS
  • 4.7. EPIDEMIOLOGICAL STUDIES OF NTRK GENE FUSIONS
    • 4.7.1. GLOBAL AND HISTORICAL TRENDS
    • 4.7.2. PREVALENCE STUDIES OF NTRK GENE FUSIONS
      • 4.7.2.1. PREVALENCE OF NTRK GENE FUSIONS IN CANCER TYPES
      • 4.7.2.2. PREVALENCE OF NTRK GENE FUSIONS BY GEOGRAPHY
      • 4.7.2.3. PREVALENCE OF NTRK GENE FUSIONS BY AGE GROUP
    • 4.7.3. INCIDENCE STUDIES OF NTRK GENE FUSIONS
      • 4.7.3.1. INCIDENCE OF NTRK GENE FUSIONS IN CANCER TYPES
      • 4.7.3.2. INCIDENCE OF NTRK GENE FUSIONS BY GEOGRAPHY
    • 4.7.4. ESTIMATED PATIENT POPULATION WHO RECEIVE TRK INHIBITORS

CHAPTER 05: DEALS (M&A) ANALYTICS OF TRK INHIBITORS

  • 5.1. DEALS (MERGERS/ACQUISITIONS/COLLABORATIONS)

CHAPTER 06: PATENT ANALYTICS OF TRK INHIBITORS PIPELINE DRUGS

CHAPTER 07: PIPELINE DRUGS ANALYTICS OF TRK INHIBITORS

  • 7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 7.1.1. PRE-REGISTRATION STAGE PIPELINE DRUGS
    • 7.1.2. PHASE III PIPELINE DRUGS
    • 7.1.3. PHASE II PIPELINE DRUGS
    • 7.1.4. PHASE I PIPELINE DRUGS
    • 7.1.5. PRE-CLINICAL PIPELINE DRUGS
    • 7.1.6. EARLY R&D PIPELINE DRUGS
    • 7.1.7. INACTIVE AND DISCONTINUED PIPELINE DRUGS
  • 7.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
  • 7.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 7.3.1. PIPELINE ANALYTICS BY ORAL ROUTE OF ADMINISTRATION
    • 7.3.2. PIPELINE ANALYTICS BY TOPICAL AND INJECTABLE ROA
  • 7.4. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 7.5. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
  • 7.6. PIPELINE DRUGS ANALYTICS BY INDICATIONS
  • 7.7. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 8.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.4. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 09: CLINICAL TRIALS SUMMARY

  • 9.1. ANALYSIS BY CLINICAL TRIAL RESULTS
    • 9.1.1. KEY PHASE III CLINICAL TRIAL RESULTS
    • 9.1.2. KEY PHASE II CLINICAL TRIAL RESULTS
    • 9.1.3. KEY PHASE I CLINICAL TRIAL RESULTS
  • 9.2. ONGOING CLINICAL TRIALS SUMMARY
  • 9.3. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
  • 9.4. PLANNED CLINICAL TRIALS SUMMARY

CHAPTER 10: ESTIMATED APPROVAL TIMELINES OF PIPELINE DRUGS

  • 10.1. METHODOLOGY
  • 10.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 11: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 12: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 12.1. EMERGING COMPANIES
    • 12.1.1. EMERGING COMPANY PROFILES
Back to Top
전화 문의
F A Q